{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mental+Disorders%2C+Severe",
    "query": {
      "condition": "Mental Disorders, Severe"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1823,
    "total_pages": 183,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mental+Disorders%2C+Severe&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T04:47:33.339Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06968390",
      "title": "Accelerated TMS for Perinatal Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Perinatal Depression",
        "Post Partum Depression",
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Transcranial Magnetic Stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2025-08-05",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06968390"
    },
    {
      "nct_id": "NCT00672620",
      "title": "Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Vortioxetine",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 611,
      "start_date": "2008-04",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 38,
      "location_summary": "Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00672620"
    },
    {
      "nct_id": "NCT00794040",
      "title": "A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mood Disorder",
        "Mental Disorder Diagnosed in Childhood",
        "Attention Deficit and Disruptive Behavior Disorder",
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Add-on citalopram following optimized methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Add-on placebo following optimized methylphenidate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 103,
      "start_date": "2008-11-17",
      "completion_date": "2018-02-01",
      "has_results": true,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00794040"
    },
    {
      "nct_id": "NCT01259427",
      "title": "Reducing Internalized Stigma in People With Serious Mental Illness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder",
        "Major Depression With Psychotic Features"
      ],
      "interventions": [
        {
          "name": "Ending Self Stigma (ESS)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health and Wellness Group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 252,
      "start_date": "2011-10",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2016-03-08",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Perry Point",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01259427"
    },
    {
      "nct_id": "NCT02454426",
      "title": "Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Vortioxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-04",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-08-25",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454426"
    },
    {
      "nct_id": "NCT00075296",
      "title": "FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 100,
      "start_date": "2004-01-05",
      "completion_date": "2008-04-21",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00075296"
    },
    {
      "nct_id": "NCT07592689",
      "title": "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "DT120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Definium Therapeutics US, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 165,
      "start_date": "2026-05-10",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 27,
      "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07592689"
    },
    {
      "nct_id": "NCT03396068",
      "title": "NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Depression",
        "Suicidal Ideation"
      ],
      "interventions": [
        {
          "name": "NRX-101",
          "type": "DRUG"
        },
        {
          "name": "Lurasidone HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeuroRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2019-12-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-01-19",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Hollywood, Florida • Fort Worth, Texas + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03396068"
    },
    {
      "nct_id": "NCT04480333",
      "title": "Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19",
        "Corona Virus Infection",
        "Severe Acute Respiratory Syndrome",
        "Severe Acute Respiratory Infection",
        "Severe Acute Respiratory Syndrome (SARS) Pneumonia",
        "Severe Acute Respiratory Syndrome of Upper Respiratory Tract",
        "Neurodegeneration",
        "Neuroinflammatory Response"
      ],
      "interventions": [
        {
          "name": "Drug: NA-831 - 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: NA-831 - 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.10 mg + 1.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.20 mg + 2.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-09-15",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 1,
      "location_summary": "Sunnyvale, California",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480333"
    },
    {
      "nct_id": "NCT02079610",
      "title": "Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "real-time fMRI neurofeedback: Amygdala",
          "type": "BEHAVIORAL"
        },
        {
          "name": "real-time fMRI neurofeedback: HIPS",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Laureate Institute for Brain Research, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-04",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-09-25",
      "last_synced_at": "2026-06-11T04:47:33.339Z",
      "location_count": 1,
      "location_summary": "Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02079610"
    }
  ]
}